Emmanouil Lymperis

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results

Berthold A. Nock, Aikaterini Kaloudi, Emmanouil Lymperis et al. · Journal of Nuclear Medicine · 2016 · 167 citations · Full text

Medicine, Oncology, Pharmacology +17

Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin

Emmanouil Lymperis, Aikaterini Kaloudi, Werner Sallegger et al. · Bioconjugate Chemistry · 2018 · 38 citations

Medicine, Nuclear Medicine, Oncology +17

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice

Aikaterini Kaloudi, Emmanouil Lymperis, Athina Giarika et al. · Molecules · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation

Aikaterini Kaloudi, Berthold A. Nock, Emmanouil Lymperis et al. · EJNMMI Research · 2016 · 31 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Improving the <i>In Vivo</i> Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon

Aikaterini Kaloudi, Berthold A. Nock, Emmanouil Lymperis et al. · Cancer Biotherapy and Radiopharmaceuticals · 2016 · 25 citations

Medicine, Nuclear Medicine, Pharmacology +17